Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BeyondSpring Inc.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Seed Therapeutics, Inc.